

# CITATION REPORT

List of articles citing

**Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation**

**DOI: 10.1046/j.1365-2036.2001.01094.x**

**Alimentary Pharmacology and Therapeutics, 2001, 15, 1655-6**

**Source:** <https://exaly.com/paper-pdf/32952066/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
396	Serotonergic neuroenteric modulators. <b>2001</b> , 358, 2061-8		136
395	New and emerging treatments for irritable bowel syndrome and functional dyspepsia. <b>2002</b> , 7, 91-8		5
394	Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 1176-81	0.7	32
393	Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2321-7	0.7	58
392	Serotonergic modulation of visceral sensation: lower gut. <i>Gut</i> , <b>2002</b> , 51 Suppl 1, i81-6	19.2	67
391	The nature of pain in irritable bowel syndrome. <b>2002</b> , 35, S26-30		6
390	Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. <b>2002</b> , 35, S58-67		53
389	Gender differences in irritable bowel syndrome. <i>Gastroenterology</i> , <b>2002</b> , 123, 1686-701	13.3	233
388	Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. <b>2002</b> , 41, 1021-42		46
387	Irritable bowel syndrome: a little understood organic bowel disease?. <b>2002</b> , 360, 555-64		222
386	Aerophagia and Intestinal Gas. <i>Current Treatment Options in Gastroenterology</i> , <b>2002</b> , 5, 259-265	2.5	6
385	Serotonergic Agents in the Treatment of Functional Gastrointestinal Disorders. <i>Current Treatment Options in Gastroenterology</i> , <b>2002</b> , 5, 293-300	2.5	1
384	A new look at irritable bowel syndrome [IBS]: a neuroenteric disorder. <b>2002</b> , 28, 222-31		7
383	New developments in the diagnosis and treatment of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2002</b> , 4, 427-34	5	16
382	A systematic review of tegaserod for the treatment of irritable bowel syndrome. <b>2002</b> , 27, 343-52		17
381	Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1701-8	6.1	61
380	A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1877-88	6.1	222

379	Serotonergic modulating drugs for functional gastrointestinal diseases. <b>2002</b> , 54, 11-20		35
378	Towards a reduction of rectal pain?. <i>Neurogastroenterology and Motility</i> , <b>2002</b> , 14, 217-9	4	16
377	Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. <b>2002</b> , 16, 869-83		26
376	Treatment of Irritable Bowel Syndrome. <i>Current Treatment Options in Gastroenterology</i> , <b>2003</b> , 6, 329-337.5		6
375	Advances in the management of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2003</b> , 5, 468-75	5	20
374	New approaches to the medical treatment of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2003</b> , 5, 337-42	5	5
373	The enteric nervous system III: a target for pharmacological treatment. <b>2003</b> , 93, 1-13		30
372	Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?. <b>2003</b> , 56, 292-6		9
371	A systematic review of tegaserod for the treatment of irritable bowel syndrome. <b>2003</b> , 28, 151-3; author reply 153		2
370	Prokinetic therapy for gastroenterological diseases. <b>2003</b> , 4, 151-159		2
369	Tegaserod, a 5-HT <sub>4</sub> receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 577-85	6.1	97
368	Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 871-80	6.1	16
367	A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 895-904	6.1	347
366	Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 18, 1031-7	6.1	74
365	Evaluation of drug treatment in irritable bowel syndrome. <b>2003</b> , 56, 362-9		50
364	Chronic constipation. <b>2003</b> , 349, 1360-8		580
363	Pharmacotherapy for intestinal motor and sensory disorders. <b>2003</b> , 32, 707-32, viii-ix		27
362	Irritable bowel syndrome: evaluation and treatment. <b>2003</b> , 32, 507-29		10

361	Sex-related differences in IBS patients: central processing of visceral stimuli. <i>Gastroenterology</i> , <b>2003</b> , 124, 1738-47	13.3	238
360	Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. <i>Drugs</i> , <b>2003</b> , 63, 1101-20	12.1	28
359	Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. <i>Drugs</i> , <b>2003</b> , 63, 1895-905	12.1	16
358	Impact of sex and gender on irritable bowel syndrome. <b>2003</b> , 5, 56-65		69
357	Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. <b>2003</b> , 25, 1952-74		25
356	A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2003</b> , 1, 111-21	6.9	65
355	Pharmacologic therapy for the irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 750-8	0.7	65
354	The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2003</b> , 1, 219-228	6.9	108
353	Irritable bowel syndrome. <b>2003</b> , 349, 2136-46		145
352	Epidemiology, pathogenesis and treatment of irritable bowel syndrome. <b>2003</b> , 13, 1213-1267		
351	Tegaserod and IBS: a perfect match?. <i>Gut</i> , <b>2003</b> , 52, 621-2	19.2	1
350	Novel therapies in the treatment of irritable bowel syndrome. <b>2003</b> , 12, 635-45		2
349	Management of irritable bowel syndrome: start of a new era?. <b>2003</b> , 15, 679-96		12
348	Management of gastroesophageal reflux disease. <b>2003</b> , 326, 309-18		16
347	Safety and tolerability of tegaserod in irritable bowel syndrome management. <b>2004</b> , 44, 41-51		5
346	Review of tegaserod in the treatment of irritable bowel syndrome. <b>2004</b> , 5, 2369-79		13
345	Pharmacology of serotonin: what a clinician should know. <i>Gut</i> , <b>2004</b> , 53, 1520-35	19.2	97
344	Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 113-21	0.7	81

343	Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 914-20	0.7	141
342	Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. <i>Neurogastroenterology and Motility</i> , <b>2004</b> , 16, 135-42	4	65
341	Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies. <i>Neurogastroenterology and Motility</i> , <b>2004</b> , 16, 701-11	4	24
340	Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 263-9	6.1	13
339	Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 805-15	6.1	12
338	The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 213-22	6.1	13
337	Diagnosis and therapy of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 2, 10-22	6.1	29
336	Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 3-14	6.1	365
335	Review article: tegaserod -- the global experience. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 15-9	6.1	7
334	Review article: the safety profile of tegaserod. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 25-30	6.1	20
333	Review article: tegaserod for chronic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 20-4	6.1	22
332	Meta-analysis: The treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 1253-69	6.1	139
331	Treating irritable bowel syndrome: overview, perspective and future therapies. <b>2004</b> , 141, 1237-48		50
330	Role of serotonin in the pathophysiology of the irritable bowel syndrome. <b>2004</b> , 141, 1285-93		157
329	Tegaserod-induced myocardial infarction: case report and hypothesis--an alternative viewpoint. <b>2004</b> , 24, 1649-50; discussion 1650-1		6
328	Tegaserod-induced myocardial infarction: case report and hypothesis. <b>2004</b> , 24, 526-31		52
327	IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. <i>Digestive Diseases and Sciences</i> , <b>2004</b> , 49, 84-7	4	41
326	Relationship of bloating to other GI and menstrual symptoms in women with irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , <b>2004</b> , 49, 88-95	4	23

325	Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. <i>Digestive Diseases and Sciences</i> , <b>2004</b> , 49, 572-4	4	24
324	Management of opioid-induced bowel dysfunction in cancer patients. <b>2004</b> , 12, 613-8		47
323	Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome. <b>2004</b> , 18, 747-71		22
322	Chronic Intestinal Pseudoobstruction. <i>Current Treatment Options in Gastroenterology</i> , <b>2004</b> , 7, 317-325	2.5	27
321	Treatment Options for Primary Constipation. <i>Current Treatment Options in Gastroenterology</i> , <b>2004</b> , 7, 225-233	2.5	9
320	Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. <b>2004</b> , 13, 803-10		8
319	Study design issues in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 141-2	6.1	6
318	Visceral pain: gender differences in response to experimental and clinical pain. <b>2004</b> , 8, 465-72		60
317	Treatment options in irritable bowel syndrome. <b>2004</b> , 18, 773-86		22
316	How to improve drug development for functional disorders. <b>2004</b> , 18, 787-96		5
315	Tegaserod: a promising option in women with irritable bowel syndrome with constipation. <b>2004</b> , 20, 1-4		
314	Enteric neuroimmunophysiology and pathophysiology. <i>Gastroenterology</i> , <b>2004</b> , 127, 635-57	13.3	184
313	Benefit-risk assessment of tegaserod in irritable bowel syndrome. <b>2004</b> , 27, 229-42		5
312	Safety profile of tegaserod, a 5-HT <sub>4</sub> receptor agonist, for the treatment of irritable bowel syndrome. <b>2004</b> , 27, 619-31		14
311	The treatment of chronic constipation in elderly people: an update. <b>2004</b> , 21, 911-30		76
310	[Latin-American consensus document on irritable bowel syndrome]. <b>2004</b> , 27, 325-43		12
309	[Pharmacological possibilities for visceral perception modulation]. <b>2004</b> , 27, 480-90		
308	Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2004</b> , 2, 796-805	6.9	144

307	Evaluation of the adolescent with chronic abdominal or pelvic pain. <b>2004</b> , 17, 23-7		6
306	Probiotics and functional abdominal bloating. <b>2004</b> , 38, S102-3		12
305	Pharmacotherapy of constipation in children. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 149-157		2
304	Gender and irritable bowel syndrome: the male connection. <b>2004</b> , 38, 546-8		5
303	Tegaserod for the treatment of irritable bowel syndrome. <b>2004</b> , CD003960		32
302	What does the future hold for irritable bowel syndrome and the functional gastrointestinal disorders?. <b>2005</b> , 39, S251-6		41
301	Irritable bowel syndrome: a syndrome in evolution. <b>2005</b> , 39, S230-42		25
300	Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. <b>2005</b> , 39, S184-93		198
299	Psychotherapeutics and serotonin agonists and antagonists. <b>2005</b> , 39, S247-50		14
298	Cilansetron: a novel, high-affinity 5-HT <sub>3</sub> receptor antagonist for irritable bowel syndrome with diarrhea predominance. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 559-567		5
297	Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity. <b>2005</b> , 6, 21-5		16
296	Overlap of gastrointestinal symptom complexes in a US community. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 29-34	4	204
295	Alvimopan, a selective peripherally acting mu-opioid antagonist. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 157-65	4	70
294	Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 500-11	4	50
293	A teaching module on irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17 Suppl 3, 20-40	4	2
292	Effect of tegaserod on gut transit in male and female subjects. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 821-6	4	71
291	Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 11-20	6.1	29
290	Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 633-51	6.1	32

289	Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 373-80	6.1	27
288	Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 1047-60	6.1	29
287	The placebo effect in irritable bowel syndrome trials: a meta-analysis. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 332-40	4	225
286	Recognizing and managing patients with irritable bowel syndrome. <b>2005</b> , 17, 51-9		9
285	Stratégie thérapeutique chez les patients atteints du syndrome de l'intestin irritable. <b>2005</b> , 35, 649-661		
284	Managing Functional Disturbances in Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2005</b> , 8, 211-221	2.5	8
283	Bloating and intestinal gas. <i>Current Treatment Options in Gastroenterology</i> , <b>2005</b> , 8, 311-8	2.5	5
282	Diagnosis and treatment of irritable bowel syndrome: state of the art. <i>Current Gastroenterology Reports</i> , <b>2005</b> , 7, 249-56	5	27
281	The role of gender and biological sex in irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2005</b> , 7, 257-63	5	10
280	The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , <b>2005</b> , 50, 2268-75	4	33
279	Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes. <b>2005</b> , 24, 2789-805		8
278	Rationale for using serotonergic agents to treat irritable bowel syndrome. <b>2005</b> , 62, 700-11; quiz 712-3		47
277	Expression and function of 5-HT <sub>4</sub> receptors in the mouse enteric nervous system. <i>American Journal of Physiology - Renal Physiology</i> , <b>2005</b> , 289, G1148-63	5.1	94
276	A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. <i>Gut</i> , <b>2005</b> , 54, 1707-13	19.2	119
275	Medical treatment of irritable bowel syndrome. <b>2005</b> , 18, 102-8		0
274	Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. <b>2005</b> , 331, 435		140
273	Traditional Chinese medicine based subgrouping of irritable bowel syndrome patients. <b>2005</b> , 33, 365-79		27
272	Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 362-72	0.7	161



271	Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care. <b>2005</b> , 71, 238-44		15
270	Recent Advances in Selective Serotonergic Agents. <b>2005</b> , 40, 17-33		10
269	Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 349-57	6.9	263
268	The use of probiotics in functional bowel disease. <b>2005</b> , 34, 533-45, x		15
267	Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. <b>2005</b> , 34, 319-35, viii		30
266	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. <b>2005</b> , 14, 185-93		45
265	Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 896-904	0.7	92
264	Getting to the bottom of chronic constipation and faecal incontinence in the elderly. <b>2005</b> , 21, 14-19		
263	Panic Attack Precipitated by Tegaserod plus Fluoxetine. <b>2005</b> , 25, 355-7		1
262	Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , <b>2005</b> , 128, 541-51	13.3	1051
261	Reply. <i>Gastroenterology</i> , <b>2005</b> , 129, 772-773	13.3	1
260	Abdominal bloating. <i>Gastroenterology</i> , <b>2005</b> , 129, 1060-78	13.3	91
259	Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 605-13	6.9	22
258	Managing nonmalignant chronic abdominal pain and malignant bowel obstruction. <b>2006</b> , 35, 131-42		6
257	Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. <i>Gastroenterology</i> , <b>2006</b> , 130, 1421-34	13.3	28
256	Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. <i>Gastroenterology</i> , <b>2006</b> , 130, 1435-46	13.3	263
255	Design of treatment trials for functional gastrointestinal disorders. <i>Gastroenterology</i> , <b>2006</b> , 130, 1538-51	13.3	252
254	[Unmet needs in the approach to irritable bowel syndrome]. <b>2006</b> , 29, 349-51		

253	Emerging drugs for irritable bowel syndrome. <b>2006</b> , 11, 293-313		7
252	Drugs acting on serotonin receptors for the treatment of functional GI disorders. <b>2006</b> , 24, 59-69		60
251	Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. <b>2006</b> , 26, 2798-807		182
250	Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. <b>2006</b> , 28, 1726-35; discussion 1710-1		137
249	Efficacy of an encapsulated probiotic <i>Bifidobacterium infantis</i> 35624 in women with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1581-90	0.7	605
248	Acupuncture for treatment of irritable bowel syndrome. <b>2006</b> , CD005111		64
247	Tegaserod in the treatment of irritable bowel syndrome with constipation. <b>2006</b> , 2, 29-42		3
246	CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME: IS RECURRENT TREATMENT WITH TEGASEROD EFFICACIOUS AND SAFE?. <b>2006</b> , 7, 44-45		
245	Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 475-484		
244	Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 191-6	6.1	68
243	Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 879-81	6.1	15
242	Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 207-36	6.1	26
241	Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 183-205	6.1	125
240	Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1655-65	6.1	40
239	Alternating bowel pattern: what do people mean?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1749-55	6.1	6
238	Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 155-62	6.1	26
237	Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 879-86	6.1	58
236	Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 859-67	6.1	20

235	The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1017-27	6.1	64
234	Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 463-9	6.1	9
233	Ion-Pair RP-LC of Tegaserod Maleate and its Impurities in Pharmaceutical Formulations and in Dissolution Studies. <b>2006</b> , 63, 431-436		3
232	Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 1297-301	4	116
231	Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. <b>2006</b> , 325, 413-22		50
230	Current gut-directed therapies for irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , <b>2006</b> , 9, 314-23	2.5	16
229	Promotility medications--now and in the future. <b>2006</b> , 24, 297-307		53
228	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. <b>2006</b> , 291, R277-84		77
227	Gastrointestinal motility disorders: an update. <b>2006</b> , 24, 228-42		35
226	Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients. <i>Gut</i> , <b>2006</b> , 55, 1409-14	19.2	28
225	Hypnosis for irritable bowel syndrome: the quest for the mechanism of action. <b>2006</b> , 54, 65-84		18
224	Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. <b>2006</b> , 73 Suppl 1, 28-37		8
223	Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT receptor agonist tegaserod. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1858-65	0.7	12
222	Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2582-7	0.7	29
221	Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1057-65	0.7	62
220	Pediatric intestinal failure: nutrition, pharmacologic, and surgical approaches. <b>2007</b> , 22, 653-63		49
219	Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1720-6	0.7	8
218	Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important?. <b>2007</b> , 5, 224-31		31

217	Irritable Bowel Syndrome. <b>2007</b> ,		
216	Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. <b>2007</b> , CD003960		57
215	Studying sex and gender differences in pain and analgesia: a consensus report. <b>2007</b> , 132 Suppl 1, S26-S45		650
214	Comparison of 5-HT <sub>4</sub> and 5-HT <sub>7</sub> receptor expression and function in the circular muscle of the human colon. <b>2007</b> , 80, 1198-205		28
213	An observational study of cholecystectomy in patients receiving tegaserod. <b>2007</b> , 30, 581-8		1
212	Chapter 13 Case History on Tegaserod (Zelnorm <sup>®</sup> /Zelmac <sup>®</sup> ). <b>2007</b> , 195-625		2
211	Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. <b>2007</b> , 36, 665-85, x		39
210	[Drug treatment of irritable bowel syndrome: an unmet need]. <b>2007</b> , 30, 130-7		
209	The serotonin signaling system: from basic understanding to drug development for functional GI disorders. <i>Gastroenterology</i> , <b>2007</b> , 132, 397-414	13.3	1011
208	Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 21, 31-7		10
207	A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 732-9	5.6	13
206	Irritable bowel syndrome: symptomatic treatment versus integrative psychotherapy. <b>2007</b> , 24, 161-177		2
205	Constipation. <b>2007</b> , 21, 709-31		64
204	Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 1183-9	4	24
203	Irritable bowel syndrome in the 21st century: perspectives from Asia or South-east Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 4-12	4	58
202	Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 1190-8	4	3
201	Is the constipated Asian male more common than we think?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 1168-9	4	1
200	Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders. <i>Neurogastroenterology and Motility</i> , <b>2007</b> , 19 Suppl 2, 32-9	4	12

199	Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. <i>Neurogastroenterology and Motility</i> , <b>2008</b> , 20, 134-41	4	25
198	Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 605-15	6.1	24
197	Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 953-61	6.1	60
196	Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 1399-407	6.1	17
195	Review article: abdominal bloating and distension in functional gastrointestinal disorders--epidemiology and exploration of possible mechanisms. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 2-10	6.1	59
194	Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study. <b>2007</b> , 10, 238-46		12
193	Tegaserod for constipation-predominant irritable bowel syndrome. <b>2007</b> , 27, 267-77		6
192	Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. <i>Neurogastroenterology and Motility</i> , <b>2007</b> , 19, 821-30	4	17
191	The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 78-83	4	29
190	The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 2942-9		67
189	Serotonin and its role in colonic function and in gastrointestinal disorders. <b>2007</b> , 50, 376-88		122
188	Cancer-related constipation. <b>2007</b> , 9, 278-84		20
187	Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do. <i>Current Treatment Options in Gastroenterology</i> , <b>2007</b> , 10, 328-37	2.5	20
186	Irritable bowel syndrome and bloating. <b>2007</b> , 21, 689-707		7
185	Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 3191-200	4	14
184	Serotonin pharmacology in the gastrointestinal tract: a review. <b>2008</b> , 377, 181-203		77
183	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. <b>2008</b> , 378, 125-37		48
182	Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 830-7	6.1	28

181	Review article: molecular, pathological and therapeutic features of human enteric neuropathies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 25-42	6.1	91
180	Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 239-49	6.1	110
179	Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. <i>Neurogastroenterology and Motility</i> , <b>2008</b> , 20, 1086-93	4	2
178	A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. <b>2008</b> , 32, 147-52		108
177	Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn. <b>2008</b> , 1, 79-88		4
176	Bloating and distention in irritable bowel syndrome: the role of visceral sensation. <i>Gastroenterology</i> , <b>2008</b> , 134, 1882-9	13.3	84
175	Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. <i>Gastroenterology</i> , <b>2008</b> , 135, 1877-91	13.3	57
174	Irritable bowel syndrome: a practical approach. <b>2008</b> , 23, 263-7		14
173	Management of chronic constipation in the elderly. <b>2008</b> , 25, 807-21		30
172	Serotonin and GI clinical disorders. <b>2008</b> , 55, 1072-80		166
171	Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. <b>2008</b> , 17, 1663-70		13
170	Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1217-25	0.7	44
169	Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1906-19	0.7	64
168	Functional GI disorders: from animal models to drug development. <i>Gut</i> , <b>2008</b> , 57, 384-404	19.2	121
167	Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. <b>2008</b> , 24, 2159-72		19
166	New treatments for irritable bowel syndrome in women. <b>2008</b> , 4, 605-22; quiz 623		14
165	Serotonin receptor modulators in the treatment of irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , <b>2008</b> , 4, 41-8	2.9	34
164	Efficacy of 5-HT <sub>3</sub> antagonists and 5-HT <sub>4</sub> agonists in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1831-43; quiz 1844	0.7	198

163	Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1998-2004	0.7	71
162	The treatment of irritable bowel syndrome. <b>2009</b> , 2, 221-38		45
161	The challenge of developing new therapies for irritable bowel syndrome. <b>2009</b> , 2, 201-3		
160	Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2009</b> , 14, 170-5	2.6	30
159	[Abdominal bloating: an up-to-date]. <b>2009</b> , 33, F94-100		2
158	Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 930-6	6.1	60
157	Pharmacological management of constipation. <i>Neurogastroenterology and Motility</i> , <b>2009</b> , 21 Suppl 2, 41-54	4	62
156	The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1033-49; quiz 1050	0.7	265
155	A multivalent approach to the design and discovery of orally efficacious 5-HT <sub>4</sub> receptor agonists. <b>2009</b> , 52, 5330-43		16
154	Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 73-9	6.9	14
153	Investigations on 5-HT <sub>4</sub> receptor expression and effects of tegaserod on human platelet aggregation in vitro. <b>2010</b> , 17, 543-52		17
152	Evaluating breath methane as a diagnostic test for constipation-predominant IBS. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 398-403	4	57
151	Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1085-9	4	22
150	Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 124-30	4	26
149	Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 144-58	6.1	149
148	Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 670-80	6.1	37
147	Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. <i>Neurogastroenterology and Motility</i> , <b>2010</b> , 22, 618-e173	4	87
146	A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. <i>Neurogastroenterology and Motility</i> , <b>2010</b> , 22, 991-8, e255	4	83

145	Abdominal Bloating and Visible Distension. <b>2010</b> , 161-168		
144	Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. <b>2010</b> , 2, 361-74		11
143	Comments on tegaserod trial on irritable bowel syndrome. <b>2010</b> , 16, 222		1
142	The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipation. <b>2010</b> , 16, 61-70		11
141	Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 731-5	0.7	31
140	[Irritable bowel syndrome, levator ani syndrome, proctalgia fugax and chronic pelvic and perineal pain]. <b>2010</b> , 20, 995-1002		8
139	Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 8, 129	6.9	27
138	Investigational agents for the irritable bowel syndrome. <b>2010</b> , 19, 1161-78		12
137	End points in irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2011</b> , 5, 293-302	4.2	2
136	Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 461-9; quiz e59	6.9	50
135	Sex and pain perception and analgesia. <b>2011</b> , 61, 814-28		36
134	Peripherally acting therapies for the treatment of irritable bowel syndrome. <b>2011</b> , 40, 163-82		11
133	Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. <b>2011</b> , 5, 253-66		59
132	[Guidelines for the treatment of irritable bowel syndrome]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2011</b> , 57, 82-99	0.6	19
131	Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. <i>Neurogastroenterology and Motility</i> , <b>2011</b> , 23, e32-9	4	19
130	Review article: the treatment of functional abdominal bloating and distension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1071-86	6.1	44
129	Management of chronic pelvic pain. <b>2011</b> , 15, 377-85		26
128	Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. <b>2011</b> , 519, 420-32		34



127	Usefulness of a slow nutrient drinking test for evaluating gastric perception and accommodation. <b>2011</b> , 84, 253-60		5
126	A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life. <b>2011</b> , 2011, 206103		22
125	The role of experimental models in developing new treatments for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2011</b> , 5, 43-57	4.2	36
124	Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 276-85	0.7	73
123	IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 286-95	0.7	54
122	Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands. <b>2012</b> , 55, 9446-66		23
121	Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 1084-93	6.1	46
120	Antibiotics for irritable bowel syndrome: rationale and current evidence. <i>Current Gastroenterology Reports</i> , <b>2012</b> , 14, 439-45	5	32
119	Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. <b>2012</b> , 5, 1-10		31
118	The effects of 5-HT <sub>4</sub> receptor agonist, mosapride citrate, on visceral hypersensitivity in a rat model. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1517-24	4	8
117	The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. <b>2012</b> , 385, 103-9		9
116	Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?. <b>2012</b> , 385, 1-3		4
115	Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V.. <b>2012</b> , 385, 1-116		3
114	An in vitro investigation of the cardiovascular effects of the 5-HT <sub>4</sub> receptor selective agonists, velusetrag and TD-8954. <b>2013</b> , 58, 150-6		21
113	Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or <i>Saccharomyces boulardii</i> . <b>2013</b> , 50, 304-9		10
112	Drug development for the irritable bowel syndrome: current challenges and future perspectives. <b>2013</b> , 4, 7		24
111	Abdominal bloating: pathophysiology and treatment. <b>2013</b> , 19, 433-53		40
110	Brain-gut axis in constipation. <b>2013</b> , 56-68		

109	Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. <b>2014</b> , 12, 3658		
108	Effectiveness of osteopathic manipulative therapy for managing symptoms of irritable bowel syndrome: a systematic review. <b>2014</b> , 114, 470-9		42
107	Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. <b>2014</b> , 79, 456-66		21
106	Pharmacological profile of DA-6886, a novel 5-HT <sub>4</sub> receptor agonist to accelerate colonic motor activity in mice. <b>2014</b> , 735, 115-22		11
105	Episodic nature of symptoms in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1450-60	0.7	29
104	Subtypes of irritable bowel syndrome in children and adolescents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1468-73	6.9	35
103	Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency pursuant to Article 13(5) of Regulation (EC) No 1924/2006. <b>2014</b> , 12, 3659		
102	Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1064-81	6.1	33
101	Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation. <i>Neurogastroenterology and Motility</i> , <b>2016</b> , 28, 581-91	4	24
100	Irritable Bowel Syndrome. <b>2016</b> , 391-399		
99	Abdominal Bloating and Visible Distension. <b>2016</b> , 412-415		
98	Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , <b>2016</b> ,	13.3	20
97	Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. <i>Neurogastroenterology and Motility</i> , <b>2016</b> , 28, 1619-1631	4	35
96	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , <b>2016</b> , 65, 82-90	19.2	67
95	Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 301-307	6.9	1
94	Sex-Related Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 1550-1560	4	25
93	Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 569-580	6.1	45
92	Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. <i>International Journal of Colorectal Disease</i> , <b>2017</b> , 32, 29-39	3	40

91	Ex vivo study of human visceral nociceptors. <i>Gut</i> , <b>2018</b> , 67, 86-96	19.2	33
90	Isobaric tags for relative and absolute quantification-based proteomic analysis that reveals the roles of progesterone receptor, inflammation, and fibrosis for slow-transit constipation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 385-392	4	8
89	[Gender Difference in Functional Gastrointestinal Disorders]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2018</b> , 72, 163-169	0.6	3
88	Human visceral nociception: findings from translational studies in human tissue. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 315, G464-G472	5.1	8
87	The Brain-Gut Axis and the Gender. <b>2019</b> , 245-253		
86	From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life. <i>Cell Cycle</i> , <b>2019</b> , 18, 1824-1829	4.7	2
85	Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain - not otherwise specified: a systematic review. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 111-125	4.1	6
84	The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. <i>Journal of Ethnopharmacology</i> , <b>2019</b> , 238, 111889	5	11
83	The influence of voltage-gated sodium channels on human gastrointestinal nociception. <i>Neurogastroenterology and Motility</i> , <b>2019</b> , 31, e13460	4	5
82	Single-cell RNAseq reveals seven classes of colonic sensory neuron. <i>Gut</i> , <b>2019</b> , 68, 633-644	19.2	114
81	Laxatives and Other Drugs for Constipation. <b>2020</b> , 333-337		
80	Efficacy and safety of 25 and 50 µg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. <i>LUTS: Lower Urinary Tract Symptoms</i> , <b>2020</b> , 12, 618	1.9	7
79	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1238-1239.e1	6.9	33
78	Constipation and Fecal Incontinence in the Elderly. <i>Current Gastroenterology Reports</i> , <b>2020</b> , 22, 54	5	10
77	Irritable Bowel Syndrome: Straightening the road from the Rome criteria. <i>Neurogastroenterology and Motility</i> , <b>2020</b> , 32, e13957	4	11
76	Bloating and Abdominal Distension: Exploring Hidden Depths and Insights. <i>Current Treatment Options in Gastroenterology</i> , <b>2020</b> , 18, 337-352	2.5	
75	Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial. <i>Gastroenterology Research and Practice</i> , <b>2020</b> , 2020, 8213082 <sup>2</sup>		3
74	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1007-1018	0.7	1

73	Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 38	12.8	9
72	Commentary: tegaserod and IBS, two decades on. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 200-201	6.1	
71	Plecanatide for the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 71-84	4.2	2
70	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , <b>2020</b> , 69, 1441-1451	19.2	53
69	Management of Chronic Abdominal Distension and Bloating. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 219-231.e1	6.9	20
68	An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 40-50	2.6	1
67	Different strains change the intestinal flora composition of mice different mechanisms to alleviate loperamide-induced constipation. <i>Food and Function</i> , <b>2021</b> , 12, 6058-6069	6.1	2
66	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1601-1611	0.7	5
65	Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
64	The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 459-473	18.8	7
63	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 98-108	6.1	4
62	Herbal Medicine for the Management of Laxative Activity. <i>Current Pharmaceutical Biotechnology</i> , <b>2021</b> ,	2.6	0
61	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
60	Scientific Evidence for the Treatment of Children with Irritable Bowel Syndrome. <i>Current Pediatric Reviews</i> , <b>2021</b> , 17, 92-102	2.8	2
59	Acupuncture for treatment of irritable bowel syndrome.		2
58	Definitions and Classifications of Irritable Bowel Syndrome. 1-21		2
57	Irritable Bowel Syndrome. 1495-1521		1
56	Treatment of irritable bowel syndrome: sex and gender specific aspects. <i>Handbook of Experimental Pharmacology</i> , <b>2012</b> , 473-97	3.2	13

55	Irritable Bowel Syndrome. <b>2004</b> , 467-475		2
54	Gender Differences in Irritable Bowel Syndrome. <b>2010</b> , 347-356		2
53	Development of the Enteric Nervous System. <b>2006</b> , 499-521		7
52	Gender-Related Differences in Functional Bowel Disorders. <b>2004</b> , 438-445		1
51	Constipation. <b>2010</b> , 259-284.e6		4
50	Irritable bowel syndrome: a practical review. <i>Southern Medical Journal</i> , <b>2006</b> , 99, 1235-42; quiz 1243-4, 1284	0.6	7
49	An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. <i>Gut</i> , <b>2003</b> , 52, 671-6	19.2	181
48	Disorders of gastrointestinal hypomotility. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	8
47	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, S8-S35	0.7	103
46	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 17-44	0.7	98
45	[Novel therapeutic approaches in the treatment of irritable bowel syndrome]. <i>Orvosi Hetilap</i> , <b>2007</b> , 148, 923-8	0.8	1
44	Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 107-18	2.9	32
43	Irritable bowel syndrome: diagnosis and management. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2020</b> , 66, 136-150	1.6	9
42	Updates on treatment of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 2639-49	5.6	44
41	Post-infectious irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 3591-6	5.6	109
40	Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord. <i>World Journal of Gastroenterology</i> , <b>2004</b> , 10, 1830-3	5.6	21
39	Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity. <i>World Journal of Gastroenterology</i> , <b>2004</b> , 10, 2836-41	5.6	13
38	Changing face of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 1-5	5.6	50

37	Recent advances in pharmacological treatment of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 8867-85	5.6	16
36	Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 8898-909	5.6	22
35	Bloating and functional gastro-intestinal disorders: where are we and where are we going?. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 14407-19	5.6	30
34	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , <b>2021</b> , e14279	4	0
33	Tegaserod. <b>2002</b> , 23,		
32	Gastrointestinal Complications. <b>2004</b> , 259-278		
31	Sex-Specific Features of Diseases of the Stomach. <b>2004</b> , 406-414		
30	Onderzoek naar sekse- en genderspecifieke verschillen bij pijn en analgesie: een consensusverslag 1. <b>2004</b> , 1287-1301		
29	Irritable Bowel Syndrome. <b>2007</b> ,		
28	Diarrhea and Constipation. <i>Translational Medicine Series</i> , <b>2008</b> , 1-20		
27	Irritable Bowel Syndrome. <b>2010</b> , 468-473.e2		1
26	Irritable Bowel Syndrome. <b>2010</b> , 355-376		1
25	Symptomatic Care Pending Diagnosis. <b>2012</b> , 1-47		
24	Obstipation. <b>2012</b> , 289-319		
23	Assessment of Consensus-Based Pharmacological Therapies in Irritable Bowel Syndrome. <i>Journal of Archives in Military Medicine</i> , <b>2015</b> , 3,	0.6	
22	Pharmacology of Serotonin and Its Receptors. <b>2020</b> , 183-212		
21	Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. <i>Drugs</i> , <b>2021</b> , 81, 1953-1968	12.1	3
20	Irritable bowel syndrome: Bacterial overgrowth—What is known and what to do. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2007</b> , 10, 328-337	2.1	

19	Obstipation. <b>2006</b> , 325-351		
18	Gastroenterological Causes of Pelvic Pain. <b>2008</b> , 117-126		
17	Cilansetron: a novel, high-affinity 5-HT <sub>3</sub> receptor antagonist for irritable bowel syndrome with diarrhea predominance. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 559-567		
16	Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 475-484		
15	Pharmacotherapy of constipation in children. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 149-157		
14	Expert commentary--bloating, distension, and the irritable bowel syndrome. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 18		5
13	IBS--review and what's new. <i>MedGenMed: Medscape General Medicine</i> , <b>2006</b> , 8, 20		7
12	Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 21 Suppl B, 3B-22B		28
11	Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. <i>Gastroenterology and Hepatology</i> , <b>2009</b> , 5, 435-42	0.7	11
10	Antibiotics for the treatment of irritable bowel syndrome. <i>Gastroenterology and Hepatology</i> , <b>2011</b> , 7, 455-93	0.7	23
9	Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?. <i>Gastroenterology and Hepatology</i> , <b>2011</b> , 7, 729-39	0.7	12
8	Gas and Bloating. <i>Gastroenterology and Hepatology</i> , <b>2006</b> , 2, 654-662	0.7	3
7	Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub-Cohort Analysis of a Phase III, Randomized, Double-Blind, Placebo-controlled Trial.. <i>Journal of Digestive Diseases</i> , <b>2022</b> ,	3.3	0
6	TEGASEROD: WHAT'S OLD IS NEW AGAIN.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	0
5	Acupuncture for irritable bowel syndrome: study protocol of a prospective, multicentre, registry study in real-world settings. <i>European Journal of Integrative Medicine</i> , <b>2022</b> , 102145	1.7	
4	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , <b>2022</b> , 163, 118-136	13.3	2
3	Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie & Motilität (DGNM) [April 2022] [AWMF-Registriernummer: 021019. <b>2022</b> , 60, 1528-1572		2
2	Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders.		0

- 1 Rescue of synaptic and cognitive functions in polysialic acid-deficient mice and dementia models by short polysialic acid fragments. **2023**, 180, 106079

o